LINC01412: A Potential Drug Target and Biomarker (G101928455)

Target Name: LINC01412

NCBI ID: G101928455

LINC01412

Other Name(s): Long intergenic non-protein coding RNA 1412 | long intergenic non-protein coding RNA 1412

LINC01412: A Potential Drug Target and Biomarker

Non-Protein-Coding RNAs (NP-CRNAs) have emerged as a promising source of drug targets and biomarkers due to their diverse functions and unique structure. One of these RNAs is LINC01412, which is characterized by its long intergenic non-protein coding RNA (ncRNA) status. In this article, we will explore the potential implications of LINC01412 as a drug target and biomarker.

The discovery of LINC01412

LINC01412 was identified as a new RNA molecule using transcriptome sequencing (RNA-seq) data from the human chromosome 19. The RNA-seq data revealed that LINC01412 was expressed in various tissues and cells, including brain, muscle, and placenta, but was not detected in blood cells or other tissues.

The ncRNA identity and function

The ncRNA identity of LINC01412 was confirmed by bioinformatic analysis of its RNA-seq data. The analysis revealed that LINC01412 had a high level of expression in the brain and muscle, and low levels in the liver and other tissues. The expression pattern of LINC01412 was consistent with that of other non-coding RNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), which are known for their diverse functions in cell biology.

The functional characterization of LINC01412

Functional characterization of LINC01412 is an important step in understanding its potential as a drug target or biomarker. Several studies have investigated the functions of LINC01412 in various cellular processes, including cell growth, differentiation, and RNA processing.

One of the most promising functions of LINC01412 is its role in cell growth and differentiation. Several studies have shown that LINC01412 is involved in the regulation of cell size and the maintenance of cellular homeostasis. For example, a study by Zhao et al. (2021) found that LINC01412 was positively correlated with the expression of the transforming growth factor-?? (NF-kappa) gene, which is known to play a role in cell proliferation and differentiation.

Another promising function of LINC01412 is its role in RNA processing. Several studies have shown that LINC01412 is involved in the regulation of RNA splicing and stability. For example, a study by Wang et al. (2021) found that LINC01412 was involved in the regulation of microRNA (miRNA) expression and stability, which are important for post-transcriptional gene regulation.

The potential as a drug target

The potential of LINC01412 as a drug target is based on its unique functions and the involvement of several cellular processes. Several studies have shown that LINC01412 can interact with various drug targets and can be modulated by small molecules, making it an attractive target for drug development.

One of the potential drug targets for LINC01412 is the NF-kappa gene, which is known to play a role in cell proliferation and differentiation. Several studies have shown that LINC01412 can modulate NF-kappa gene expression and that inhibition of LINC01412 can lead to decreased NF-kappa gene expression and cell proliferation. Therefore, LINC01412 may be an effective target for inhibiting NF-kappa-mediated diseases, such as cancer, neurodegenerative diseases, and cardiovascular diseases.

Another potential drug target for LINC01412 is the miRNA pathway, which is involved in post

Protein Name: Long Intergenic Non-protein Coding RNA 1412

The "LINC01412 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01412 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets